A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection

Inclusion Criteria:

1. Male or female, at least 18 years of age at time of screening.

2. Screening laboratory result indicating HCV GT1 infection.

3. Chronic HCV infection.

4. Subject must be HCV treatment-naïve (i.e., patient has never received a single dose
of any approved or investigational regimen) or treatment-experienced (has failed
prior IFN or pegIFN with or without RBV, or SOF plus RBV with or without pegIFN
therapy).

5. Subjects must be non-cirrhotic.

Additional Inclusion Criteria for GT1 HCV/HIV-1 co-infected patients:

6. HIV-1 ART naïve with CD4 ≥ 500 cells/mm3 (or CD4+ % ≥ 29%) at Screening and plasma
HIV-1 RNA <1,000 copies/mL at Screening and at least once during the 12 months prior
to Screening.

Or On a stable, qualifying HIV-1 ART regimen for at least 8 weeks prior to screening, with
CD4 ≥ 200 cells/mm3 (or CD4+ % ≥14%) at Screening and plasma HIV-1 RNA < LLOQ at Screening
and at least once during the 12 months prior to Screening.

Exclusion Criteria:

1. History of severe, life-threatening or other significant sensitivity to any
excipients of the study drugs.

2. Female who is pregnant, planning to become pregnant during the study or
breastfeeding; or male whose partner is pregnant or planning to become pregnant
during the study.

3. Recent (within 6 months prior to study drug administration) history of drug or
alcohol abuse that could preclude adherence to the protocol in the opinion of the
investigator.

4. Positive test result at Screening for hepatitis B surface antigen (HBsAg).

5. HCV genotype performed during screening indicating co-infection with more than one
HCV genotype.

6. Chronic human immunodeficiency virus, type 2 (HIV-2) infection.